StemCell Therapy

Feb 18, 2020 7:00 AM

More than 30 million people in the United States have diabetes. About seven million of those people dont know they have it. Symptoms of untreated diabetes include:

Believe it or not, erectile dysfunction (ED) can also be a symptom of diabetes. In fact, half of men diagnosed with diabetes experience ED within ten years of their diagnosis.

We see quite a few men for erectile dysfunction that end up being diagnosed with diabetes after their visit with us. Most people dont think about the penis being an indicator of other, underlying health issues, but it really is a good barometer.

In order to get an erection, men need healthy blood vessels and nerves. High blood sugar levels, a symptom of diabetes, can damage blood vessels as well as the nerves that control sexual stimulation. Because diabetes can cause the inner lining of blood vessels to function abnormally, it can affect blood flow to the penis, which is how you get and maintain an erection.

Managing your diabetes can stop the progression of ED, but sometimes symptoms dont improve because of nerve damage. There are many treatment options for ED if you dont see an improvement after getting your diabetes under control.

Oral medications typically work about 50 percent of the time for men with diabetes. Penile pumps are also good options, if medications dont work. Other men may choose injection therapy, which is a treatment where you inject the penis with a small needle when you want an erection.

Penile implants are another ED treatment. Implants last 1215 years on average.

All of these treatment options have pros and cons. Men should consider what works best for their lifestyles when chatting with their provider about the best choice for them.

Erectile dysfunction is frustrating and stressful for men and their partners. Its not something people should just live with, Dr. Hotaling said. If youre struggling with ED, talk to your health care provider. Sometimes its an unrelated problem. Other times, its linked to something more serious, like diabetes or heart disease. Regardless, its worth getting treated.

Read the original here:
Diabetes and ED: Symptoms, Treatment - University of Utah Health Care

Positive results have been announced from part 2 of the phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D).

TTP399 is a novel, once-daily, liver-selective glucokinase activator. Simplici-T1, a multi-center, randomized, 12-week trial, investigated the efficacy and safety of 800 mg of TTP399 compared with placebo in 85 patients with T1D on optimized insulin therapy.

The trial successfully achieved its primary objective, which was analyzed using 2 statistical approaches to evaluating the effect of TTP399. The primary statistical analysis evaluated the effect on long-term blood sugar (HbA1c) regardless of treatment adherence or notable change in insulin administration.

Under the primary statistical analysis, the trial achieved its primary objective by demonstrating statistically significant improvements in HbA1c for TTP399 compared with placebo at week 12.

TTP399 was well tolerated with similar incidences of treatment-emergent adverse events (AEs) overall and by system organ class in both treatment groups. The study had no report of diabetic ketoacidosis in either treatment group. There was no incidence of severe hypoglycemia in the treated group and 1 incident in the placebo group.

Patients taking TTP399 experienced fewer symptomatic hypoglycemic episodes: 2 subjects taking TTP399 reported at least 1 AE compared with 8 subjects taking placebo.

In order to rule out that the reduction of HbA1c was driven by the administration of excess insulin (3 or more units per day), a second statistical analysis was performed. Based on this analysis, patients treated with TTP399 achieved a statistically-significant, placebo-subtracted reduction in HbA1c. Patients taking placebo experienced a 0.11% increase in HbA1c from a mean study baseline HbA1c of 7.6% following a multi-week insulin optimization period prior to the administration of study treatment.

Daily time in range was improved by approximately 2 hours in patients treated with TTP399 relative to placebo (p=0.03). TTP399 treatment reduced the total daily meantime bolus insulin dose by 11% relative to baseline (p=0.02), whereas the placebo-treated group experienced a 3% decrease relative to baseline.

TTP399 selectively activates glucokinase (GK), a key regulator of glucose metabolism in the liver. This activation has been shown to increase glucose utilization, which in turn lowers blood glucose. Simplici-T1 is the first study to test activation of GK in patients with T1D, evaluating daily oral TTP399 as an adjunct to insulin therapy.

Reference

See original here:
Oral Adjunctive Therapy Yields Positive Results for Adults with Type 1 Diabetes - Pharmacy Times

Diabetes is one of the largest, most expensive problems facing America's veterans, and the US government is staking its hopes for a solution on an unconventional treatment: the popular keto diet.

The Department of Veterans' Affairs (VA) has launched a partnership with a digital therapeutics startup Virta Health to treat diabetic veterans using the low-carb, high-fat keto diet, at no cost to the vets or the VA.

The partnership, first announced in May 2019, has enrolled 400 veterans into Virta's program, which includes personalized nutrition plans and online access to health coaches and physicians.

So far, the results have been promising, according to the company's data. A pilot program with the VA found that half of the participating veterans achieved blood sugar levels below the threshold for diabetes after three months on Virta's program. And the treatment successfully reduced medications, including insulin, by 53% across the entire group.

But some experts have raised concerns that there may be unforeseen health consequences following this kind of treatment, and that the VA's buy-in will lend legitimacy to what is still an experimental treatment.

Prior to working with the VA, Virta had been studying keto as a treatment for diabetes for over two years.

Diabetes is an inability to balance blood sugar.Reducing carbs manages the problem at the source by preventing blood sugar from rising in the first place, according to Dr. Mark Cucuzzella, a professor at West Virginia University School of Medicine, a US Air Force Reservist, and a marathon runner who has published several studies on keto and diabetes.

Hollis Johnson/INSIDER "The most impactful thing on your blood glucose is the amount of carbs in your diet. The low-carb diet is effective because it lowers the insulin load," Cucuzzella, whois not affiliated with Virta, told Insider in an interview. "Insulin is the master switch."

Medications like insulin can mitigate diabetes symptoms by managing blood sugar levels. But keto can help patients reduce medications, said Dr. Sarah Hallberg, medical director for Virta.

Eating carbohydrates causes blood sugar to rise, but eating fats does not. It means diabetic patients can get their daily calories without needing to use insulin to balance out spiking blood sugar levels.

"Standard treatment puts people on a one-way street of progression for diabetes, with temporary pharmaceutical treatment that will have to be added on to," Hallberg told Insider. "We're able to give people another lane going the other way by bringing blood sugar into non-diabetic range while reducing and eliminating medication."

That doesn't mean keto can cure diabetes.

Virta refers to its treatment as a "reversal" of diabetes. In layman's terms, this means the disease is in remission. The treatment only works as long as the low-carb diet is maintained. As soon as carbs are re-introduced, the same problems with blood sugar and insulin emerge.

A keto diet is any eating plan that pushes the body into a state of ketosis when it begins producing substances called ketones, explained Dr. Ethan Weiss, a cardiologist and founder of a ketone-detecting device. (Weiss previously served as a medical advisor for Virta.)

"Keto" typically refers to eating plans in which a majority of daily calories come from fat, along with some protein and minimal carbs.People with diabetes could cut their carb intake to as low as 30 grams a day and still be healthy.

But the key to medical keto is going beyond counting macronutrients. Instead, it's important to focus onwhole-food sources of fats, cutting carbs without completely eliminating nutrient-rich foods like veggies.

Vietnam war veterans among other guests listen to U.S. President Barack Obama at the Memorial Day observance at Arlington National Cemetery in Washington, U.S., May 30, 2016. REUTERS/Yuri Gripas

It's not clear what long-term health effects the keto diet might have.

The Physicians Committee for Responsible Medicine, a group of medical experts who advocate a plant-based diet, sent a letter to VA officials asking them to reconsider the partnership, and keto treatment, based on evidence that a high-fat, low-carb diet could potentially increase risks of diabetes, particularly diets high in saturated fat.

Skeptics have also noted that most of the data showing keto can treat diabetes is based on studies led and funded by Virta itself. There is barely any hard data on keto's health effects beyond two years on the diet.

Hallberg acknowledged the lack of long-term evidence, but said the same problem has plagued nearly every other type of therapeutic diet (with the exception of the Mediterranean diet).

"There's needs to be a hard outcome, long-term trial looking at a variety of eating patterns, no question," she said.

But in the meantime, diabetes continues to be diagnosed in record numbers, particularly among military veterans.

"Do we have 10-20 years to wait for that?We're in the midst of an unprecedented diabetes and obesity epidemic," she said. "We have to do something now."

Read more:

Nutrition experts react to the keto diet's new ranking as one of the worst diets of 2020

There's a Mediterranean version of the keto diet that restricts red meat and trades butter for olive oil

The keto diet makes mice better at fighting the flu another clue about how the high-fat, low-carb plan changes the body

View original post here:
Keto diet is being used by government to treat veterans' diabetes - Insider - INSIDER

Submitted Published 5:02 a.m. ET Feb. 17, 2020

Afterschool children promote the Y's upcoming participation in the major countywide fundraiser, Give Where You Live Collier.(Photo: Photo provided)

As fundraisers go, this one is a biggie for the YMCA of South Collier (Marco Y).

In a nutshell, the Y collects money for a Countywide drive called Give Where You Live Collier, and then gets it back (and then some) by way of matching funds.

The major fundraiser serves 40 pre-selected non-profits (of which the Marco Y is one) that will benefit from the 24-hour fundraiser taking place noon Feb. 19 to 11:59 a.m. Feb. 20.

Aquatics, sports and specialty camps director Morgan Joseph instills the importance of physical activities to some of the Y's early learners (pre-school).(Photo: Photo provided)

The participating organizations do their own fundraising, and money raised is swelled with matching funds from the Community Foundation of Collier County and Richard M. Schultze Family Foundation.

This year, Marco's Y is focusing its campaign on diabetes prevention and supporting its specialty summer camps for diabetic children.

On-site nurse Monica Ramos delights an early learning (pre-school) student by letting her hear heartbeats.(Photo: Photo provided)

Described as a "growing epidemic," diabetes cases (including types 1 and 11) have risen more than 30 percent since 2000, with many more going undiagnosed until a medical crisis occurs.

The Y's development director, Charlie Vickaryous, notes that 2020 will mark the third year that the organization has partnered with Help a Diabetic Child and Core Health Partners to provide the camp.

Depending on money raised, a second camp is envisaged. In addition, the Y will incorporate an extensive diabetes prevention and intervention program into all summer camp sessions, which serve more than 600 children throughout southern Collier County.

The YMCA of South Collier is a major human service organization providing support for all ages and all income levels throughout Southern Collier County, including Marco, Goodland, East Naples, Everglades City and surrounding areas. More than 10,000 people 2,000 of whom are children benefit each year.

For more information, contact Vickaryous at commdev@marcoy.org - or call 394-9622.

Read or Share this story: https://www.marconews.com/story/news/2020/02/17/funds-help-y-focus-diabetes/4771791002/

Original post:
Funds will help Y to focus on diabetes - Marco News

According to the Center for Disease Control and Prevention, more than 100 million U.S. adults are now living with diabetes or pre-diabetes.

At the Mississippi Gulf Coast YMCA in Ocean Springs, they are trying to lower that number with their Diabetes Prevention Program.

This program provides a supportive environment where participants work together in a small group to learn about healthier eating and increasing their physical activity in order to reduce their risk for developing diabetes. Community Impact Director Jodi Ryder said, You know, we have such a high incidence of type two diabetes and type two diabetes is preventable. The biggest cause of type two diabetes seems to be linked to lifestyle, not making the right food choices, not getting enough activity, and carrying excess weight.

If you are interested in participating in this class contact the YMCA at 228-875-5050 for more information.

Here is the original post:
Diabetes Prevention Program at the Gulf Coast YMCA - WXXV News 25

Women who survive domestic abuse are more likely to suffer from heart disease, diabetes, and all-cause mortality, which refers to death from any cause, a study has revealed. Researchers found that women in the U.K. who lived through domestic abuse were 31 percent more likely to develop heart disease, and had a 51 percent higher chance of having type 2 diabetes. The participants also had a 44 percent higher risk of dying from any cause. The authors of the study examined data from the medical records of tens of thousands of women in the U.K. who visited doctors between Jan. 1, 1995 and Dec. 1, 2017. They matched the data of 18,547 women who had experienced domestic abuse by age and lifestyle with women who had not suffered from domestic violence.

Domestic abuse was defined as any incident or patterns of incidents of controlling, coercive, threatening behavior, violence or abuse between those aged 16 or over who are, or have been, intimate partners or family members regardless of gender or sexuality. Domestic abuse victims were more likely to drink, at 10.1 percent compared to 3.5 percent in the other group.

See the original post here:
Women Who Survive Domestic Abuse at Higher Risk of Heart Disease, Diabetes: Study - The Daily Beast

Is Type 1 diabetes dramatically more common than is widely understood? Thats the contention of Dr. David Leslie, Professor of Diabetes and Immunology at London Universitys Blizard Institute.

In the United States, about 30 million people are said to have diabetes. Of those, about 1 million are diagnosed with Type 1, and the other 29 million are diagnosed with (or suspected of having) Type 2. But is that ratio accurate? Or does it reflect a misunderstanding of the nature of Type 1 diabetes?

Dr. Leslie thinks the real numbers will definitely be different:

The number of people with Type 1 is probably much higher than weve accounted for. That 29 million something like 2 million of them may have undiagnosed Type 1.

The misdiagnosis of Type 1 diabetes is already a known problem. Its easy for doctors to confuse Type 1 with Type 2, especially among adult patients and those displaying some of the indicators of the latter condition, such as obesity. A recent study from the University of Exeter last year showed that 38% of patients with Type 1 diabetes occurring after age 30 were initially treated as Type 2 diabetes, and, even more strikingly, that half of those misdiagnosed were still diagnosed as Type 2 diabetes 13 years later.

According to Dr. Leslie, even these numbers may underreport the problem: In our research, of those adults who presented with [Type 1] diabetes, the ratio of those that did not require insulin, compared to those who did, was about 3:1.

Dr. Leslie is a recognized leader in the world of diabetes research, having served as principal investigator on several major European trials. We were first alerted to his work when a fascinating paper that he authored came across the ASweetLife desk: C-peptide persistence in type 1 diabetes: not drowning, but waving?

The paper, published in the journal BMC Medicine, discusses surprising amount of variance in C-peptide persistence in people with Type 1 diabetes. While it was once thought that everyone with T1D rapidly declined towards zero insulin production, what we now know is that C-peptide persistence varies widely across a spectrum. Most people with T1D retain at least some ability to produce insulin, even after many years, and many retain so much that they havent even been identified as having T1D.

And so the old image of T1D as a disease of the young is gradually getting turned on its head. Various studies have shown that among T1D patients requiring insulin immediately, just as many were diagnosed in adulthood as in childhood. Thats without counting the unknown millions that have a mild or slow-developing form of the disease and have yet to be identified.

Dr. Leslie told me, I see patients every week who are diagnosed in adulthood and are told, Thats it, Type 2, end of story. They dont get the antibodies test. Every week I see people like that. When Dr. Leslie tests them, he will often learn that they do have the autoantibodies that define Type 1 diabetes.

Dr. Leslie explained that it only became evident as late as the 1970s that adults were developing variants of Type 1 diabetes that did not require insulin. In the years since, researchers have begun to identify a bewildering diversity of specific types of Type 1 diabetes, each with their own unique criteria, such as LADA, MODY and SPIDDM. But even while awareness of adult-onset diabetes and these associated conditions has grown, many experts still tend to view Type 1 diabetes through the prism of our old understanding of it as a juvenile or insulin-dependent disease. It was only within the last decade, for example, that the Juvenile Diabetes Research Foundation officially changed its name to JDRF.

The old stereotypes are still strong. When I was diagnosed (as an adult) I had more than a few people express surprise that it was even possible for an adult to develop T1D. One too-confident acquaintance told me that I was in error, and that I had Type 2. Unfortunately, many on the front lines of diabetes, such as the primary care providers and family doctors that are often the first to see a patient with the symptoms of hyperglycemia, still cling to these old assumptions.

Dr. Leslies contention reminds us that proper diabetes management requires self-examination and self-advocacy. Diabetes is not a disease that allows one to simply accept a doctors prescription uncritically. Patients themselves have the primary responsibility of monitoring their own blood sugar levels and evaluating the success of their medicine, diet, lifestyle and exercise choices.

Sometimes, unfortunately, the need for self-advocacy extends even to question of the diagnosis itself.

Read more from the original source:
Is Type 1 Diabetes Much More Common than We Think? - A Sweet Life

Women who survive domestic abuse are more likely to develop heart disease, diabetes, and die of any cause, a study has revealed.

Researchers found women in the U.K. who experienced domestic abuse were 31 percent more likely to develop heart disease, and had a 51 percent higher chance of having type 2 diabetes. The participants were also 44 percent higher risk of what is known as all-cause mortality.

Lead author of the study Dr. Joht Singh Chandan, public health doctor at the University of Warwick and University of Birmingham, told Newsweek "all-cause mortality" refers to death from any cause.

He explained: "So in these records we can't discern the exact cause, we just know the patient had died."

The authors of the paper published in the Journal of the American Heart Association looked at data from the medical records of tens of thousands of women in the U.K. who visited doctors between January 1, 1995 and December 1, 2017.

A total of 18,547 women had experienced domestic abuse, and their data was matched by age and lifestyle with four women (72,231 in total) who hadn't experienced domestic violence, to compare their health. The participants were aged 37 on average.

Domestic abuse was defined as "any incident or patterns of incidents of controlling, coercive, threatening behavior, violence or abuse between those aged 16 or over who are, or have been, intimate partners or family members regardless of gender or sexuality."

Some 27.1 percent of women in the U.K. on average suffer domestic abuse at some point in their lives. In the U.S., one in four women and one in nine men experience some form of intimate partner violence or stalking, according to the National Coalition Against Domestic Violence.

The participants were more likely to come from deprived areas compared with the national U.K. average, and 44.7 percent smoked. Women who experienced domestic abuse were more likely to drink than the other group, at 10.1 percent versus. 3.5 percent.

But domestic abuse survivors were still more likely to have conditions like heart disease and diabetes even when researchers accounted for these variables, suggesting their lifestyles were not the only explanation for higher risk, the team said. More research is needed to understand how to help these women and pinpoint what might explain the link, the authors said.

However, Chandan said the study was limited because cases might not be accurately recorded.

"It is clear that domestic abuse is heavily under-recorded in GP [family doctor] records and so there may be individuals in the control group who have experienced abuse but are miscoded as not experiencing abuse. However, in reality this may mean we are under-estimating the findings," he explained.

Chandan said he wanted to conduct the study because he is both a medical doctor and a volunteer detective for West Midlands Police force in the U.K. "I see lots of survivors of abuse with poor health and wanted to understand why as well as how we can best support them," he said.

Read more:
Women Who Survive Domestic Abuse More Likely to Develop Heart Disease, Diabetes, Die of Any Cause - Newsweek

Grace Lieberman, Cronkite News

Originally Published: February 18, 2020 11:54 a.m.

PHOENIX Cooking equipment at the ready, Mallory Smith stands before a table loaded with fresh greens, nuts and fruit.

Has anyone used the apple slicer before? she asks the dozen people gathered this weekday morning at Native Health. Might take a little bit of practice.

Over the next hour, Smith chopped, mixed and scooped as she demonstrated how to make a chicken Waldorf salad as part of a new class to encourage diabetes-friendly cooking to help diabetics manage their blood sugar.

A lot of people in the Native American community and in the Phoenix community, they get diagnosed with diabetes but arent necessarily educated on it, Smith said. Having this class helps them find out what diabetes is, what kind of foods they can eat with diabetes, what can help them for their overall health.

The 20-week course, which is free and open to anyone, is held morning and evening every Thursday through June 4. Each week, Smith demonstrates a new recipe, and participants go home with free groceries to replicate the dishes at home.

Food for Thought is part of Native Healths diabetes management program for the Native American community. Michelle Hill, a certified diabetes educator at Native Health, said the goal is to show patients that eating properly can be easy, accessible and economical.

More than 30 million Americans have diabetes, according to the American Diabetes Association. That includes 695,000 Arizonans or 12.5 percent of the adult population.

Both nationally and in Arizona, Native Americans have the highest rates of the disease, followed by blacks and Hispanics. More than 19 percent of adult Native Americans in the state have been diagnosed, the Arizona Department of Health Services reports.

Type 1 diabetes is a condition in which the body does not produce any insulin, which helps regulate blood sugar. In the more common type 2 diabetes, the body produces insulin but does not use it properly. Some people only need to maintain a healthy diet and exercise regimen to manage the disease, while others might need insulin injections or other medicines.

In order to properly regulate their blood sugar, diabetics are cautioned against eating foods high in processed sugar, such as white bread, sugary cereals and flavored yogurt and drinks. Hill told participants they should not be afraid to eat natural sugar found in whole fruits.

Glorene Barton learned about Food for Thought from her health care providers during a recent appointment at Native Health.

I was asking about snacks, because Im a diabetic and I forgot to bring a snack with me. So she told me about this class that might be interesting for me, Barton said. I learned a few different things about eating and grams and carbs and things of that nature. It was interesting.

Another participant, Marla Wilson, said her son motivates her to keep up with a healthy diet. She thought this program was a great opportunity to learn how.

I have a son whos very health-conscious. So Im sure hell like it, too, because we were just talking about eating more salads and the health benefit, Wilson said.

Participants learned they can test their bodies reaction to new foods by trying them over a few days, then checking their blood sugar levels two hours later each time.

Where it was time to get cooking, with Smith guided the group through the process.

The ingredient that surprised people the most was nonfat yogurt, which was used along with lemon juice to dress the salad. Smith said yogurt is an excellent substitute for less healthful ingredients, such as sour cream.

At the end, participants were able to take home both dry goods and fresh produce funded by the Mobilize AZ project from Blue Cross Blue Shield of Arizona.

Being diabetic is a very expensive way of being, and so this is a plus, Wilson said. We get what we need to make our dinner tonight.

See the rest here:
Health provider offers cooking classes to address high rates of Native diabetes - Navajo-Hopi Observer

SEATTLE , Feb. 18, 2020 /CNW/ --LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in Diabetic Retinopathy (DR).

"Recent research in our labs in both preclinical and clinical areas have indicated potential in treating diabetic edema with PBM," stated Janis Eells , Ph.D., Professor, University of Wisconsin-Milwaukee . "Our work shows that early PBM benefits in reducing the detrimental effects of high glucose on retinal cells and early human data is now starting to show benefits in the clinical setting."

DR is the leading cause of blindness in the world. The International Diabetes Foundation 2019 Fact Sheet estimated that globally 463 million people have diabetes now, and future estimates suggest that this number will increase to 578 million by the year 2030.

"We have been working with Dr. Eells and the University of Wisconsin-Milwaukee on our dry AMD research and the work in DR and Diabetic Macular Edema (DME) is a logical extension of our PBM platform," stated Clark E. Tedford , Ph.D., President and CEO of LumiThera, Inc. "The results from Dr. Eell's lab point to the multiple cellular benefits of treating the disease early and PBM would be an alternative approach for treatment of early disease."

LumiThera was granted a CE mark to commercialize the Valeda System in European Union for the treatment of ocular diseases including dry AMD.The company previously announced that the National Institutes of Health and division of the National Eye Institute have provided a $2.5M grant to support the LIGHTSITE II multi-center clinical trial to lead to U.S. approval for dry AMD.The Company is enrolling two multi-center trials, one in European Union and one in the US for dry AMD. The entry into DME provides a second major ocular disease platform for the Valeda system.

"We are excited to be involved in the development of Valeda for both non-neovascular (dry) AMD and DME. We are currently enrolling patients in the LIGHTSITE III study and believe that PBM could be an even bigger platform for DME," remarked Quan Dong Nguyen , M.D., M.Sc. and Diana V. Do, M.D., Professors of Ophthalmology at the Byers Eye Institute, Stanford University . "DME is the leading cause of functional vision loss among working adults worldwide. Treatments with intravitreal injections of pharmacologic agents are effective but can be costly and invasive. PBM could provide a significant improvement to the current practices with its non-invasive approach."

"I am continually impressed with the scientific foundation that LumiThera is building for PBM with collaborations in both preclinical and clinical research," stated David Boyer , M.D., Retina-Vitreous Associates Medical Group. "The benefits for PBM on multiple critical cellular pathways involved in the disease etiology in preclinical work is now being evaluated in the clinical setting and could change the way we address chronic disease that leads to blindness."

Visit the Company's website at http://www.lumithera.com.

About LumiThera Inc.LumiThera is a commercial-stage medical device company focused on treating people affected by ocular disorders and diseases including dry AMD, a leading cause of blindness in adults over 65 and DR, the leading cause of blindness in the world. The company is a leader in the use of PBM for treatment of acute and chronic ocular diseases and disorders. The company is developing the office-based Valeda Light Delivery System to be used by eye care specialists for medical treatment.

The Valeda Light Delivery System has been granted authorization to use the CE Mark by an EU Notified Body as required for commercial use in the European Economic Area only. Valeda is not approved for use by the Food & Drug Administration (FDA) in the USA .

2020 LumiThera, Inc., All rights reserved.

View original content:http://www.prnewswire.com/news-releases/lumithera-to-expand-research-into-diabetic-retinopathy-for-valeda-light-delivery-system-301006356.html

SOURCE LumiThera Inc.

View original content: http://www.newswire.ca/en/releases/archive/February2020/18/c7986.html

More:
LumiThera to Expand Research into Diabetic Retinopathy for Valeda Light Delivery System - Yahoo Finance

Research study on Global Type-1 Diabetes Treatment Market Examination of Market Segmentation Including Product Type, Application, And Regions

Global Type-1 Diabetes Treatment Market comprises the estimation of the market including industry analysis, size, share, growth, trends, outlook, and forecasts 2019-2024. Global Type-1 Diabetes Treatment the industry is just the resource that players need to strengthen their overall growth and establish a strong position in their business. The report analyzes historical data, facts, current growth factors, and market threats with a competitive analysis of major market players. The report covers consumption, revenue, sales, production, trends, opportunities, geographic expansion, competition, segmentation, growth drivers, and challenges. The report presents the scope of different segments and applications that can potentially influence the global market in the projection period from 2019 to 2024.

Get a Sample Copy at:https://www.mrinsights.biz/report-detail/214865/request-sample

The report represents the aspects and descriptions of the global Type-1 Diabetes Treatment market by maps, bar graphs, pie diagrams, and other visual representations. It gives top to bottom investigation of the potential portions including item type, application, end client and their commitment to the general market size. It further covers the present situation and the development possibilities of the industry for 2019-2024. Research experts have utilized industry-best essential and auxiliary research approaches to organize this meticulous and complete research study on the worldwide market.

The well-established key players in the market are:Astellas Pharma, Abbott Laboratories, Merck, Novo Nordisk, Sanofi, Eli Lilly, Novartis, AstraZeneca, Pfizer Inc., Boehringer Ingelheim GmbH, Mannkind Corporation, Macrogenics, Inc., Braun Melsungen AG

The report explores Type-1 Diabetes Treatment business policies, trading, market channels, market volume, providers of raw material and customer data, demand & supply ratio. Geographic division relies on:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Key Details Outlined In The Report:

The report deals with the key factors driving the commercial landscape of the global Type-1 Diabetes Treatment market over the analysis period. Market share and growth rates accounted for by every application over the estimation timeline are encompassed in the report. It provides analysis on the industry chain scenario, key market players, market volume, upstream raw material details, production cost, and marketing channels. The report covers analysis on consumption volume, region-wise import/export analysis and forecast market from 2019-2024.

ACCESS FULL [emailprotected]https://www.mrinsights.biz/report/global-type-1-diabetes-treatment-market-growth-status-and-214865.html

Destinations of The Research Study:

Moreover, the report gives revenue estimates of the global Type-1 Diabetes Treatment market based on top industry players, their product type, applications, and regions. It has mentioned the production volume and consumption volume during the forecast period. Then, the sale worth is for varied sorts, applications, and regions also are enclosed.In addition, sort wise and application wise consumption figures also are provided.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

See the original post here:
Global Type-1 Diabetes Treatment Market | Industry Size, Growth Opportunities, Competitive Analysis and Forecast to 2024 - Nyse Nasdaq Live

Two Co Down students have become the stars of a new series of videos - which have gone viral - aimed at making it okay to have diabetes. Best friends Ellen Watson (19) and Beth McDaniel (20), from Banbridge, are smashing the stigma of Type 1 diabetes - a lifelong condition that causes a person's blood sugar level to become too high and for which daily injections of insulin are needed - thanks to their hugely popular TikTok videos.

alling themselves the Diabetic Duo, the young women have amassed hundreds of thousands of followers in just a few months through their refreshing, light-hearted posts about living with Type 1 diabetes.

TikTok is a popular video-sharing social network service used to create short film clips which can last from three to 15 seconds.

After posting their first video last October, Ellen and Beth knew they had hit a nerve when it was viewed overnight by 500,000 people and eventually scored more than 700,000 hits.

They were then inundated with messages from young people around the globe congratulating them on raising awareness about living with diabetes.

Ellen and Beth - who are both studying at Ulster University - live together, work together at the weekends, are cheerleaders and love to shop.

We use our free style libras to check our blood sugar levels using our phones they are a gift from god #fyp #diabeticduo #belfast #trending

Ellen has lived with diabetes since the age of six and was shocked when Beth was diagnosed just last September.

The two friends support each other, counting calories to ensure their diets are healthy and keeping tabs on monitoring blood sugar levels.

Ellen knows what it's like to grow up under the shadow of diabetes, having tried to hide it for years from her school friends, which is why she is thrilled that the videos are having such a big impact.

"I grew up with diabetes and have had it for as long as I can remember," she says. "When I was really young I just did what my mum told me and then as I got older I had to learn to keep an eye on my sugar levels myself.

"I became really conscious of it in high school when I was 13. I didn't want people to know I had it and I would have tried to inject myself under the table in the canteen at lunchtime without anyone knowing.

"When I got a bit older I did grow to accept it a bit more and see the positive side. I have great community support with my doctor and nurses who are all lovely and show you how to live with it.

"My mum Sharon is a nurse and she always kept me right. New technology has really helped make life with diabetes a lot easier."

Ellen was on hand to support her best friend Beth when she was diagnosed in September of last year - incredibly, within just a week of her 12-year-old sister also being diagnosed.

Injecting in strange places#diabeticduo #foryoupage #belfast #holylands #t1dcat #hypo #trending

"We have no family history of diabetes but last August my little sister Grace took sick and was diagnosed with diabetes which was a big shock for our family," Beth says.

"Seven days later, on September 4 - a day I will never forget - I, too, was diagnosed. My parents were still in shock over Grace's diagnosis and just couldn't believe it when I was told I had it, too.

"I knew it was diabetes as I had all the symptoms. I was really sluggish and didn't want to get out of bed and was very thirsty. I also had blurred vision and I felt very irritable.

"I believed in my head that I had it and my dad took to me to hospital where it was diagnosed. My mum was devastated.

"At first I found it really hard to come to terms with and I cried every day for the first two weeks.

"I never liked needles and I would have sat staring at my belly for 10 minutes before plucking up the courage to inject myself.

"The finger-pricking to check blood sugar levels was also really sore.

"Ellen and I share accommodation at university and we just sit at the dinner table some nights and laugh because we always shared everything and we can't believe we now both have diabetes.

"We inject at the same time and we both count our calories to make sure we are eating property.

"Ellen has been such a huge support and I really wouldn't have coped so well over the last few months without her."

A great support to each other, the girls have been inseparable since they first met four years ago while working in the same shoe shop in their home town of Banbridge.

They hit it off immediately and not only did they have a lot of interests in common, but they both looked alike.

"We just clicked and everyone thinks we are twins because we look so much like each other," Beth laughs.

"We even picked similar courses at the same university. Ellen is studying marketing at the Ulster University and I'm studying communications, advertising and marketing.

"We also live together in the same student accommodation and that has brought us even closer together."

Type 1 diabetes is different to Type 2 - the latter is usually associated with lifestyle, in particular being overweight, and presents later in adult life.

Ellen and Beth say that a general lack of understanding in the difference between the two is a huge reason why they believe there is a stigma surrounding living with diabetes.

People with Type 1 diabetes are insulin-dependent as their pancreas produces little or no insulin - the hormone which regulates blood sugar.

People with Type 2 diabetes can manage the disease with a healthy lifestyle and diet. However, most also have to take medication.

The girls have been breaking down barriers by recording videos showing them openly injecting insulin and proudly wearing their sugar monitoring discs on their arms during nights out.

A new device called the FreeStyle Libre is a glucose-monitoring disc which can be worn on the arm and, linked to a phone app, monitors blood sugars automatically. While you may still need to do some finger-prick tests, this nonetheless provides an enormous benefit.

Indeed, Ellen says it has revolutionised how she is able to manage her diabetes and even her mum has access to the same app which displays a graph of her blood sugar levels throughout the day.

Wearing the arm sensor, which is around the size of a two-pence piece, on their videos has endeared them to other young people who felt the need to hide their diabetes.

When you and your bestie have a hypo at the same time #diabeticduo #fyp #belfast #foryoupage #hypo #trending #besties

The students aim to keep their videos funny while promoting the message that it is okay to have diabetes.

They have been astonished by the reaction.

"I was constantly asked if I was overweight as people automatically assume that is why I have diabetes and with the videos we've been able to shatter that myth," Ellen says.

"People are quite shocked that we are young and eat well and look after ourselves and still have diabetes.

"We already did some fun videos as 'the iconic duo' as we are always together and always doing the same thing and even wear the same outfits.

"We thought we should make one for the craic for TikTok and add diabetes as an element - overnight it went viral with half a million views and in the end more than 700,000 people watched it and we just couldn't believe it. People saw the scanner on our arms and were shocked that we would wear it so openly on a night out.

"For us it is a way to create a bit of fun out of a lifelong illness.

"We've had messages from all over the world, from Scotland, Australia and America, and we just seem to be getting more and more every day.

"Many are from children and young people our age who are asking us questions and, while we know we are not in a position to give medical advice, we are happy to support people who contact us.

"I feel that it really would have helped me if I had something similar to look out for when I was younger as there was no one I knew my age who had diabetes and who I could relate to."

Close

Fun times: The Diabetic Duo are often mistaken for twins

Kevin Scott

Beth agrees and adds: "It is all about changing the stigma as a lot of people don't understand the difference between Type 1 and Type 2 diabetes. I love how we are inspiring people and it's great to be able to post positive things online.

"I think it is really important to bring positivity to it with a bit of fun at the heart of it. People can be really negative about it and we are glad to be able to bring it out in the open and show we are not uncomfortable with it.

"We've done a range of funny videos including one where we pretended to be our nurses checking our blood cells and the nurses and doctors in our local practice said they loved it.

"We also did one on injecting insulin in strange places and we videoed ourselves injecting in front of a police car, while doing our cheerleading and eating a sausage roll in Greggs and that was viewed by half a million people.

The response has been incredible and we are constantly having people come up to us in shops and the street recognising us as the Diabetic Duo. We feel like local celebrities!"

You can watch Ellen and Beth on the TikTok app via @diabeticduo. Beth also writes a beauty blog you can find at bethymcdaniel.wordpress.com

The number of people in Northern Ireland living with Type 1 and Type 2 diabetes is now 100,000, according to figures published by http://www.diabetes.org.uk. This number includes the estimated 12,000 who have not yet been diagnosed with Type 2 diabetes.

Prevalence of diabetes in NI is now over 5.7% and approximately 90% of diabetes cases are Type 2, the NI Audit Office reports.

Type 1 diabetes

Type 1 has no relation to diet or lifestyle and it is not clear what causes it.

The cells of the pancreas which make insulin are attacked which means that insulin production is suppressed.

Because insulin regulates blood sugar, without this control in place glucose levels in the blood build up.

Symptoms: before diagnosis, your body tries to remove glucose through the kidneys, which means you go to the toilet a lot.

The patient can be very thirsty, feel tired more than usual, lose weight unexpectedly and have blurred vision. These symptoms can present within days or weeks and the patient should seek medical attention as soon as possible.

Managing Type 1 diabetes: insulin must be injected or delivered to the body via a pump. Blood sugar levels should be checked several times a day.

Type 2 diabetes

Six out of 10 people have no symptoms when they're diagnosed with Type 2 diabetes. However, symptoms are similar to those for Type 1.

Managing Type 2 diabetes: most people need medicine to help keep blood sugar levels as normal as possible. Sticking to a healthy diet and keeping active will help you manage blood sugar.

Around 2.5 hours of activity a week is recommended - this could include fast walking, climbing stairs and doing more strenuous housework or gardening.

Losing weight if you're overweight is important as it will help your body to lower your blood sugar level, and can improve blood pressure and cholesterol.

Regular monitoring and check-ups are important as complications of Type 2 diabetes can include heart disease and stroke, nerve damage, foot problems, vision loss and kidney problems.

Sources: http://www.diabetes.org.uk and http://www.nhs.uk

Read the original post:
Northern Ireland 'Diabetic Duo' who have gone viral with online videos that smash stigma of life with the illness - Belfast Telegraph

CLEVELAND, Feb. 18, 2020 (GLOBE NEWSWIRE) -- DiasomePharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin to optimize treatment for people living with diabetes, today announced positive results from its Phase 2 OPTI-1 study of injectable hepatocyte directed vesicle (HDV) added to mealtime insulin in people with type 1 diabetes (T1D).

One of the trials investigators, Bruce Bode, M.D., a diabetes specialist with Atlanta Diabetes Associates and clinical associate professor in the Department of Medicine at Emory University, added, The OPTI-1 study may be the first clinical trial to demonstrate the impact of the combined effects of liver targeted insulin and physiologically driven changes in the ratio of mealtime to long-acting insulin regimens. These results provide additional evidence that targeting insulin to the liver induces a more physiological response. When added to insulin, HDV may allow patients to optimize the amount of short-acting and long-acting insulin they need to reduce the incidence of hypoglycemia while still achieving positive long-term health outcomes.

This open-label, multicenter study was designed to evaluate the effect of HDV added to rapid-acting mealtime insulin on A1C, hypoglycemia, and bolus and basal insulin dosing in adult T1D patients with baseline A1C levels between 6.5% and 8.5%. Patients underwent a three-month run-in period on standard-of-care therapy followed by three months of treatment with HDV added to mealtime insulin in conjunction with optimized basal insulin doses. A total of 61 T1D patients were enrolled at eight United States trial sites. After patients were treated with standard-of-care Lispro or Degludec during the run-in period, they were randomized into one of two groups: HDV-Lispro (HDV-L) in conjunction with a 10% reduction in Degludec or HDV-L in conjunction with a 40% reduction in Degludec.

The completion of this clinical trial marks an important milestone for the continued development of HDV, said Robert Geho, chief executive officer of Diasome. Results from this study, which we plan to present at upcoming conferences, continue to support the hypothesis that improved mealtime insulin delivery to the liver should have an important and positive effect on overall glycemic control. We are excited about these results and look forward to sharing additional details soon.

About Hepatocyte Directed Vesicle (HDV) TechnologyHDVs are the most advanced technology designed to restore normal physiology and potentially offer protection against hypoglycemia for patients with diabetes. Only 20-50 nanometers in size, these two-layered microscopic discs are designed to bring insulin to receptors highly expressed by liver cells. Liquid HDV can be mixed with any commercially available insulin prior to administration and is compatible with any insulin delivery system.

About Type 1 Diabetes (T1D)T1D is a chronic, auto-immune disease characterized by the inability of the pancreas to produce insulin, which leads to elevated blood sugar levels. Diabetes costs represent a large burden to both patients and the healthcare system. More than 1.25 million Americans are living with T1D and there is no cure.

About OPTI-1The 24-week, open-label, multiple dose trial is designed to assess the safety, tolerability and efficacy of hepatocyte directed vesicle (HDV) technology when added to rapid-acting mealtime insulin. All patients received insulin Lispro and Degludec during a 12-week run-in period. After completing the run-in period, patients were randomized to a treatment group of either HDV added to Lispro (HDV-L) while continuing Degludec at a dose reduced by 40% or HDV-L while continuing Degludec at a dose reduced by 10% for 12 weeks of treatment.

About Diasome Pharmaceuticals, Inc.Diasomes hepatocyte directed vesicle (HDV) technology is the only pharmaceutical insulin additive being developed to prevent hypoglycemia by restoring normal liver physiology in patients with diabetes. HDV technology is a Phase 3-ready asset designed to improve the safety and efficacy of all insulins. For more information, visit http://www.diasome.com or follow us on Twitter.

Investor Contact:Jeremy FefferLifeSci Advisors, LLCjeremy@lifesciadvisors.com+1.212-915-2568

Media Contact:Cherilyn Cecchini, M.D.LifeSci Communicationsccecchini@lifescicomms.com+1.646.876.5196

See original here:
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes - GlobeNewswire

Type 2 diabetes is a condition which results in the body losing control of the amount of glucose in the blood, causing blood glucose levels becoming too high. If blood glucose isnt controlled properly and stays too high, it can lead to a number of problems, including kidney failure, nerve damage, heart disease and stroke.

Eating a regular poor diet can increase a persons risk of developing type 2 diabetes, so making diet changes is recommended.

Carbohydrates you eat and drink are broken down into glucose, and the type and amount you consume can make a difference to a persons blood glucose levels and diabetes management.

So when it comes to one of the famous carbohydrates, bread, what type is considered best or what advice should you follow?

Diabetes UK explains: There are two types of carbohydrate: starchy carbohydrates and sugars.

READ MORE:How to live longer: People with this condition 50 percent more likely to die early

Bread falls into the starchy carbohydrate category. All carbohydrates affect blood glucose levels.

Carbohydrate requirements vary between individuals and depend on age, gender, weight and physical activity.

The Reference Intake (RI) of carbohydrate is 230g for women and 300g for men.

These figures are just a guide and are based on the requirements of an average woman and man. Depending on your nutritional goals, you may require less.

DON'T MISS

Most supermarkets and local markets contain different types of bread, the type diabetes charity offers advice for next time youre choosing a loaf.

Per slice, the following types of bread contain:

These could be served with lean chicken, ham, turkey or beef plus chopped tomatoes, grated carrot and cucumber, or reduce-fat cheddar with grated carrot and sultanas.

Sourdough, rye and soda bread may be served with turkey, chicken or Swiss cheese with shredded lettuce, tomatoes and reduced-fat mayo.

These types of bread contain:

Brioche can be served warm with jam or pure fruit spread. It contains:

Garlic and ciabatta bread contain:

Garlic and ciabatta breada are often available to buy already sliced. so you can control your portion sizes.

Naan and chapatti contain:

Diabetes UK says you should try to avoid adding extra butter, margarine or ghee.

The NHS states theres nothing you cannot eat if you have type 2 diabetes, but certain foods should be limited.

It advises: You should eat a wide range of foods including fruit, vegetables and some starchy foods like pasta, keep sugar, fat and salt to a minimum, and eat breakfast, lunch and dinner every day do not skip meals.

Continued here:
Type 2 diabetes: Best bread to choose if you want to lower blood sugar - Express

Tandem Diabetes Care, Inc. (TNDM) is priced at $86.03 after the most recent trading session. At the very opening of the session, the stock price was $86.34 and reached a high price of $87.19, prior to closing the session it reached the value of $83.02. The stock touched a low price of $84.51.

Tandem Diabetes Care, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $83.91 on 02/14/20, with the lowest value was $45.61 for the same time period, recorded on 02/26/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Tandem Diabetes Care, Inc. shares are logging 2.53% during the 52-week period from high price, and 88.62% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $45.61 and $83.91.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.83 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Tandem Diabetes Care, Inc. (TNDM) recorded performance in the market was 44.32%, having the revenues showcasing 37.34% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.91B, as it employees total of 653 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 64.59, with a change in the price was noted +21.14. In a similar fashion, Tandem Diabetes Care, Inc. posted a movement of +32.58% for the period of last 100 days, recording 1,484,676 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for TNDM is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Tandem Diabetes Care, Inc. in the period of last 50 days is set at 96.09%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 94.45%. In the last 20 days, the companys Stochastic %K was 93.36% and its Stochastic %D was recorded 92.18%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 44.32%. Additionally, trading for the stock in the period of the last six months notably improved by 50.64%, alongside a boost of 74.57% for the period of the last 12 months. The shares increased approximately by 10.47% in the 7-day charts and went down by 15.07% in the period of the last 30 days. Common stock shares were driven by 37.34% during last recorded quarter.

See the rest here:
Analysts Mean recommendation for Tandem Diabetes Care, Inc. (TNDM) was 2.00: Is this the key time? - The InvestChronicle

In a couple weeks, he'll go to South America. A few months ago, he traveled to India and this summer he will return. Omaha eye surgeon, Dr. Donny Suh, (pronounced "saw"), is no stranger to volunteer mission trips, first traveling to offer his expertise and services more than 20 years ago with the vising saving organization, Orbis. "I feel very honored and privileged," said Suh, who took a moment from his work as Chief of Pediatric Opthalmology at Children's Hospital and Medical Center, to talk about his volunteer work. Suh also teaches at the University of Nebraska Medical Center and he see patients at Nebraska Medicine where he tackles the most challenging eye issues. He recently returned from a trip to Bihar State, India, where he helped with hospital based training doing cataract surgeries on children. Suh supervised 18 surgeries with trained Indian doctors, showing them how to use the latest surgical equipment provided by the non-profit, Orbis. "This place was particularly advanced. But they were using equipment that was 20 to 30 years old," he said.Surgeons in that hospital perform about 300 surgeries a day. Orbis has 400 volunteer faculty worldwide from more than 30 countries working to prevent blindness around the globe. In Omaha, Suh said he might see two or three children per week with cataracts. About a billion people worldwide have a vision issue that could be prevented or hasn't been addressed. Suh said pediatric cataracts are very common in India because of malnutrition, poor prenatal care and a lack of immunizations. Cataracts make the lens of the eye more opaque, blocking light and causing blindness. "We were in the poorest part of India where everyone lives day to day," said Suh. He said the team of doctors and nurses worked out of an inspiring eye hospital which served multiple purposes. He said the man who built Akhand Jyoti Hospital/School saw the need to serve some of the poorest people on Earth, but also he built it as an educational opportunity to hire girls to work there, train, study, play soccer, and become optometrists."He saw that a lot of girls were being married as teenagers and wanted more for them," said Suh. He said more than 500 young women are now working as eye doctors. Suh often talks about the role vision plays in all aspects of life, especially for a growing child."Vision is responsible for 75 to 85-percent of development. Sight is not just sight. It gives people hope," said Suh. He said he's seen multiple children over the years who couldn't even take their first steps until they were able to see others walk and model the behavior."They would get up and walk the very next day after surgery," he said.KETV has reported on Suh in the past, featuring his efforts to bring vision screenings, training, and an eye clinic to Guatemala. The South Korea native who grew up in dire poverty with his brother and single mom said it's his mission to give back to others, especially in third-world countries. In his recent book, "Catching a Star: My Story of Hope", Suh talks about his childhood, his desire to help others, and life-changing encounters with patients.He writes about a mother who gave birth to a child with multiple genetic and health challenges including a lack of clear vision because of cataracts. Doctors said the baby had just months to live. Suh said the mother begged him to do eye surgery on the child so that when her baby met her in heaven one day, the child would recognize her face. Suh said he was deeply moved by the mother's request and told her, "I will give you my 100-percent so that the baby can see you after surgery."He said, the next day, the baby couldn't stop staring at the mother's face. The child is now 3 and a half years old. "It's truly incredible," said Suh. He believes vision played a large part in helping the child to live. All proceeds from the sale of Suh's book will go toward medical missions and helping children to see. His book is available on Amazon.

In a couple weeks, he'll go to South America. A few months ago, he traveled to India and this summer he will return. Omaha eye surgeon, Dr. Donny Suh, (pronounced "saw"), is no stranger to volunteer mission trips, first traveling to offer his expertise and services more than 20 years ago with the vising saving organization, Orbis.

"I feel very honored and privileged," said Suh, who took a moment from his work as Chief of Pediatric Opthalmology at Children's Hospital and Medical Center, to talk about his volunteer work. Suh also teaches at the University of Nebraska Medical Center and he see patients at Nebraska Medicine where he tackles the most challenging eye issues.

Dr. Suh takes pride in helping to train eye surgeons with the latest technology.

He recently returned from a trip to Bihar State, India, where he helped with hospital based training doing cataract surgeries on children. Suh supervised 18 surgeries with trained Indian doctors, showing them how to use the latest surgical equipment provided by the non-profit, Orbis.

"This place was particularly advanced. But they were using equipment that was 20 to 30 years old," he said.

Surgeons in that hospital perform about 300 surgeries a day.

Orbis has 400 volunteer faculty worldwide from more than 30 countries working to prevent blindness around the globe.

In Omaha, Suh said he might see two or three children per week with cataracts.

About a billion people worldwide have a vision issue that could be prevented or hasn't been addressed.

Dr. Donny Suh has volunteered on mission trips for 20 years.

Suh said pediatric cataracts are very common in India because of malnutrition, poor prenatal care and a lack of immunizations. Cataracts make the lens of the eye more opaque, blocking light and causing blindness.

"We were in the poorest part of India where everyone lives day to day," said Suh. He said the team of doctors and nurses worked out of an inspiring eye hospital which served multiple purposes. He said the man who built Akhand Jyoti Hospital/School saw the need to serve some of the poorest people on Earth, but also he built it as an educational opportunity to hire girls to work there, train, study, play soccer, and become optometrists.

"He saw that a lot of girls were being married as teenagers and wanted more for them," said Suh. He said more than 500 young women are now working as eye doctors.

Suh often talks about the role vision plays in all aspects of life, especially for a growing child.

"Vision is responsible for 75 to 85-percent of development. Sight is not just sight. It gives people hope," said Suh.

He said he's seen multiple children over the years who couldn't even take their first steps until they were able to see others walk and model the behavior.

"They would get up and walk the very next day after surgery," he said.

KETV has reported on Suh in the past, featuring his efforts to bring vision screenings, training, and an eye clinic to Guatemala.

The South Korea native who grew up in dire poverty with his brother and single mom said it's his mission to give back to others, especially in third-world countries.

Suh and his brother were born in South Korea.

In his recent book, "Catching a Star: My Story of Hope", Suh talks about his childhood, his desire to help others, and life-changing encounters with patients.

He writes about a mother who gave birth to a child with multiple genetic and health challenges including a lack of clear vision because of cataracts. Doctors said the baby had just months to live. Suh said the mother begged him to do eye surgery on the child so that when her baby met her in heaven one day, the child would recognize her face.

Suh said he was deeply moved by the mother's request and told her, "I will give you my 100-percent so that the baby can see you after surgery."

He said, the next day, the baby couldn't stop staring at the mother's face. The child is now 3 and a half years old. "It's truly incredible," said Suh.

He believes vision played a large part in helping the child to live.

All proceeds from the sale of Suh's book will go toward medical missions and helping children to see.

His book is available on Amazon.

Originally posted here:
Omaha eye surgeon travels the world to offer vision and hope - KETV Omaha

Santen has forged two separate partnerships with Googles life sciences sister company Verilyand the International Telecommunication Union (ITU) whose initiative is supported by the World Health Organisation (WHO).

Both partnerships are aimed to drive the expansion of the latest technological innovations and digital solutions in ophthalmology across Europe and globally.

Combining Santens technology in the ophthalmology field and Verilys expertise in Artificial Intelligence (AI) and building hardware and software-based devices, the new company plans to develop and commercialise ophthalmic devices, including IoT medical devices.

Shigeo Taniuchi, president and COO of Santen said: Santen has actively promoted collaboration and open innovation with various external organisations in order to enhance the Quality of Life for people around the world through eye health. Digital technology is a transformational driver in health and we hope that this joint venture will be a significant step forward in transforming the way of eye care for people around the world.

Dimitri Azar, clinical lead, Opthalmology Programmes at Verily added: We are thrilled to partner with Santen, a global company with an established presence in the ophthalmology industry, to develop novel solutions leveraging AI and microelectronics for better eye care. By combining Santens eye care expertise and Verilys advanced technology, our joint venture is well-positioned to tackle innovative projects in ophthalmology diseases such as glaucoma, dry eye and other opthalmological diseases. Well explore ways to use technology not only to diagnose disease, but to improve disease management, and ultimately, further precision medicine in ophthalmology.

ITU will support Be He@lthy, Be Mobile (BHBM) and will focus preventable non-communicable diseases in the ophthalmology area with the aim of achieving eye health. BHBM is a digital health initiative between the WHO and the ITU in support of the WHO's expansion of services in non-communicable diseases.

This initiative is designed to raise awareness of the prevention and management of non-communicable diseases through the use of mobile phones and digital devices in order to realise healthy lifestyles. It is estimated that almost the entire world population (97%) lives within reach of a mobile cellular signal, and today its service is expanding digital health services and geographic reach, including the distribution of health information and content to end users through SMS (short message service) and digital device apps.

Doreen Bogdan-Martin, director of the ITU Telecommunication Development Bureau, said: "The participation of Santen in BHBM initiative highlights the importance of investing in technologies which can empower people to manage their own health and for medical professionals to better provide care from prevention to diagnosis and treatment. At ITU, we are expanding our partnership and collaboration with various stakeholders in order to bring the benefits of technology to the people, in every area and every walk of life."

The rest is here:
Santen forges ophthalmology partnerships with Verily and WHO - Med-Tech Innovation

The market report envelopes an all-in information of the global Connective Tissue Growth Factor market and the nature of the market growth over the foreseeable period. The report provides a comprehensive elaboration of the positives and negatives of the global Connective Tissue Growth Factor market with DROT and Porters Five Forces analysis. With SWOT analysis, the report offers detailed insights about different players operating within the Connective Tissue Growth Factor market. In addition, the analysts of the report have served the qualitative and quantitative scrutinizing of different micro- and macro-economic factors influencing the global Connective Tissue Growth Factor market.

The Connective Tissue Growth Factor market report examines the consumption patter of each segment and the factors affecting the pattern. In addition, the report focuses on the production footprint of each segment in various industries and regions across the globe.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2550879&source=atm

The Connective Tissue Growth Factor market report helps the readers grasp the changing trend in the industry supply chain, manufacturing techniques and expenses, and current scenario of the end uses in the global Connective Tissue Growth Factor market.

All the players running in the global Connective Tissue Growth Factor market are elaborated thoroughly in the Connective Tissue Growth Factor market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Connective Tissue Growth Factor market players.

The following manufacturers are covered:BLR Bio LLCFibroGen IncProMetic Life Sciences IncRXi Pharmaceuticals Corp

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeBLR-200IB-DMDOLX-201PBI-4050Others

Segment by ApplicationHypertrophic ScarsOpthalmologyGenetic DisordersLiver FibrosisOthers

Reports at discounted rates exclusively for new entrants!!! Offer end by midnight!!!

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2550879&source=atm

The Connective Tissue Growth Factor market report answers the following queries:

What the report encloses for the readers:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2550879&licType=S&source=atm

Why choose Connective Tissue Growth Factor Market Report?

See the article here:
Connective Tissue Growth Factor Market Size, Share, Top Region, Key Players, Application,Status and Forecast 2027 - Redhill Local Councillors

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (dry AMD), have been accepted for presentation at the 2020 Association for Research in Vision and Ophthalmology (ARVO) Meeting, which will be held May 3rd through May 7th, 2020 at the Baltimore Convention Center in Baltimore, MD. The abstract presentation, entitled, "Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results", will be presented as part of the Gene Therapy and Stem cells Session on May 3rd, 2020 from 3:00PM to 4:45PM EDT by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute and University of Cincinnati School of Medicine; Clinical Governance Board, Cincinnati Eye Institute (presentation number 865). The presentation will provide updated data from patient cohorts 1 through 4 of the clinical study and will include data on the first patients dosed with both a new subretinal delivery system as well as with a new Thaw-and-Inject (TAI) formulation of OpRegen.

"We continue to be encouraged by positive data with OpRegen for the treatment of dry AMD," stated Brian M. Culley, CEO of Lineage. "The five patients treated as part of cohort 4, which more closely match our intended patient population, have all demonstrated an increase in the number of letters they can read on an Early Treatment Diabetic Retinopathy Scale (ETDRS), having gained between 10 25 letters. Importantly, the first patient treated using both a new subretinal delivery system and our TAI formulation of OpRegen demonstrated notable improvements in vision, having gained 25 readable letters (or 5 lines) 6 months following administration of OpRegen RPE cells, as assessed by the ETDRS. This represents an improvement in visual acuity from a baseline of 20/250 to 20/100 in the treated eye. These visual acuity measurements are meaningful and can translate into quality of life enhancements to things like reading, driving, or avoiding accidents. With the opening of two leading ophthalmology research centers as clinical sites for our study, we are focused on rapid enrollment so that our clinical update at ARVO can be as mature and informative as possible. Our objective is to combine the best cells, the best production process and the best delivery system, which we believe will position us as the front-runner in the race to address the unmet opportunity in the potential billion-dollar dry AMD market."

In addition, Lineage will present new preclinical results from its Vision Restoration Program, a proprietary program based on the ability to generate 3-dimensional human retinal tissue derived from pluripotent cells. Lineages 3-dimensional retinal tissue technology may address the unmet need of implementing a retinal tissue restoration strategy to address a wide range of severe retinal degenerative conditions including retinitis pigmentosa and advanced forms of AMD. In 2017 and 2019, the Small Business Innovation Research program of the National Institutes of Health awarded Lineage grants of close to $2.3 million to further develop this innovative, next generation vision restoration program.

- The poster presentation, entitled, "Transplantation of organoid-derived human retinal tissue in to the subretinal space of CrxRdy/+ cats)," will be presented as part of the Animal models for visual disease and restoration Session on May 4th, 2020 4:00PM to 5:45PM EDT in Session Number 291 by Igor Nasonkin, Ph.D., Principal Investigator, Director of Research & Development at Lineage (Poster board Number: 2253 - B0162).

- The poster presentation, entitled, " Intraocular biocompatibility of Hystem hydrogel for delivery of pharmaceutical agents and cells," will be presented as part of the Stem cells and organoids: Technical advances Session on May 5th, 2020 between 8:45AM to 10:30AM EDT in Session Number 332 by our collaborator Randolph D. Glickman, Ph.D., Professor of Ophthalmology, UT Health San Antonio (Poster board Number: # A0247).

Story continues

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical programs are in markets with billion dollar opportunities and include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia, a facial aesthetics product that was recently granted a Conformit Europenne (CE) Mark. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," project," "target," "tend to," or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the potential applications in Lineages Vision Restoration Program. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineages business and other risks in Lineages filings with the Securities and Exchange Commission (the SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Lineages periodic reports with the SEC, including Lineages Annual Report on Form 10-K filed with the SEC on March 14, 2019 and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005395/en/

Contacts

Lineage Cell Therapeutics, Inc. IR Ioana C. Hone(ir@lineagecell.com) (510) 871-4188

Solebury Trout IR Gitanjali Jain Ogawa(Gogawa@troutgroup.com)(646) 378-2949

View original post here:
Lineage Cell Therapeutics to Present New Data From OpRegen and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology...

Share This Article:Mike Bloomberg has a new fan in retired San Diego business journalist and columnist Don Bauder (inset). Photos by Chris Stone, Ellen BauderAt 83, San Diego journalism legend Don Bauder is guarding his health playing hermit at home (to avoid the flu) and venturing out only for doctor visits.

Support Times of San Diego's growthwith a small monthly contribution

Bauder, a Colorado resident since 2003, was forced by heart issues to retire in 2018 as a San Diego Reader columnist. But now he admits hell be questioned about his mental health.

Hes backing Mike Bloomberg for president.

Here I am finally making headway against the heart problems and now I am considered a candidate for the loony bin, Bauder said by email Wednesday.

If exercise and multiple trips to doctors and hospitals will repair my brain as they seem to have helped my heart, I feel I can thwart oncoming dementia, although I have never claimed that I am either stable or a genius as President Donald Trump has. I am at least stable enough to hope that my candidate will not choke on verbal borscht, as Trump does almost every day.

Bauder isnt wearing beet-colored glasses, though.

He concedes that the former New York City mayor once stated that if women wanted to be known for their intelligence, they would spend less time at Bloomingdales and more time at the library.

Bloomberg called the remark a Borscht Belt joke, Bauder said.

The former San Diego Union-Tribune financial editor also noted that Bloomberg once stated that 95% of murderers are male minorities, 15 to 25 who deserve to be pushed up against the wall.

Bauder adds: Democrats desperately need the votes of women, African-Americans and Latinos. New Yorkers have told me that those minorities will never forget, although Bloomberg has renounced his widely criticized stop-and-frisk policy that clearly discriminated against minorities while he was mayor of New York.

But it wasnt until former U-T colleague Logan Jenkins outed himself as a Bloomberg fan that Bauder also emerged from the closet at least locally.

Bauder wrote Times of San Diego:

As a former newspaper columnist and magazine writer, I agree wholeheartedly with Logan Jenkins. After a lot of pondering, I have concluded that Bloomberg is the ideal Democratic candidate. I started out backing Biden, but have become quite disenchanted. Unlike Trump, Bloomberg is a self-made billionaire.

Unlike Trump, who is clearly a sociopath on steroids, as well as a pathological liar and malignant psychotic narcissist, Bloomberg is eminently stable and also brilliant, as he proved in his business career and as mayor of New York City. I would add one thing to what Logan says: we desperately need a female on the ticket. As shown in 2018, females can see through Trump.

I would suggest Kamala Harris; her minority status would help balance the ticket. I worry that Bloombergs stop and frisk mistake will continue to turn off minorities.

Like Bloomberg, Bauder is a former Republican. (From 1960 to 1964, when he was in advertising and PR, Bauder voted for Richard Nixon.)

Since 2004, he says, hes voted for Democratic presidential candidates.

This year, however, I had problems, he wrote Wednesday. I feared that both Bernie Sanders and Elizabeth Warren had gone too far. I dont like Medicare for All. Those who want to keep their private plans should be able to do so. I cant see free higher education for all. Frankly, I think too many students are in college now.

Bauder calls student debt a cancerous problem, but cant see canceling it out.

Should we reimburse those who have already paid off their debt? I cant see giving stipends to families descended from slaves, he said. If anybody deserves to be paid off, its Native Americans, from whom we stole our country.

He said his cautious views left him with moderate choices.

I originally favored Joe Biden, but became disenchanted quickly. I liked Amy Klobuchar from the beginning, and I am happy to see her rising fast, he said. Pete Buttigieg is quite intelligent but needs seasoning. Ditto Tom Steyer.

Bauder considers the 2020 election critical.

Four more years of Trump would be disastrous, he said. Yes, I am concerned about more Russian hacking. Given the close 2016 races in Wisconsin, Michigan and Pennsylvania, we should all worry about Russian hacking this year.

Climate change is the most critical issue for Bauder because if the world doesnt do more to curb greenhouse gases, the world as we know it may suffocate by the end of the century.

This interview was conducted via email.

Times of San Diego: What does Mike Bloomberg offer?

Don Bauder: First: money. Lots of it. Hes worth close to $60 billion, making him 14th-richest in the world, according to Forbes. Unlike Trump, Bloomberg made the money himself. And he is ACTUALLY worth that.

Trump may not even be a billionaire, despite his claims to be worth $10 billion. The biggest advantage of Bloombergs wealth is that he can flood the nation with ads showing that Trump is a phony. Indeed, Bloomberg is already doing that, but you aint seen nuthin yet.

The Democratic Party is hurting for money. Bloomberg is NEEDED. He has not alienated the business community. Right now, money is flowing to Republican coffers because big business particularly pharmaceuticals, insurance, oil and the like is terrified of Sanders and Warren. That river of cash will slow down if the leftists are out of the picture.

As he has proved as New York mayor, Bloomberg is socially liberal and progressive. He supports abortion rights, government-funded stem cell research, same-sex marriage, gun control, environmentalism and routes to citizenship for illegal immigrants.

He is strong on public welfare and is a national leader in the battle against climate change. He wants to enhance the earned income tax credit. But unlike the other candidates, he has support from many in the business community. He is in favor of free trade. He is a fiscal conservative. He balanced New York Citys budget. Facing a crisis, he talked a Republican state Senate into passing a tax increase rather than slashing jobs.

He opposes wealth inequality proposing, for example, that his own taxes should go up. He says generally that taxes for the rich should rise. He would raise corporate taxes from 21% to 28% percent not enough in my judgment, but a good start.

He dislikes the fact that taxes on stock and bond gains are lower than income taxes. He would enhance worker rights and benefits although he has never been considered pro-union. He wants a $15 an hour minimum wage. He favors government-financed welfare projects. He believes rural communities should be more closely connected with urban centers.

During his political career, he has been a Republican, an independent and a Democrat. He knows his way around politics, having been mayor of New York City from 2002 to 2013.

He cracked one time that a short Jew would never be elected president, but I question that. He will absolutely eat up Trump in a debate. It will be obvious that he is 10 times smarter than Trump.

(Bauder cites the same metric in the San Diego mayors race, saying he favors Barbara Bry because of her intelligence.)

Your journalism career is marked by major investigations into scam artists and political boondoggles. What gives you confidence that Bloomberg has genuine concern for the common good and not himself and his affluent cohort?

He favors corporate welfare corporate projects partly funded by government. I consider most such projects to be scams, although few others do. As mayor of New York, he has warned the citizenry of scam artists on the loose. But early in his mayoral term he vetoed a bill against predatory lending.

Why should Sen. Kamala Harris be Bloombergs running mate?

First, the Democrats must have a female on the ticket on the top of the ticket or the vice president. If Bloomberg is at the top, a female must run for the second slot. A minority female would be greatly preferred. Kamala Harris fills that bill. Stacey Abrams or Oprah Winfrey (who says she doesnt want it) would also be excellent.

If Bloomberg doesnt break out in Super Tuesday voting, will he have a shot at winning enough delegates to prevail at Milwaukee Democratic National Convention?

If Bloomberg does poorly, he will have to consider dropping out. If he does drop out, he should continue giving his planned donations to the Democratic Party. Ditto Tom Steyer. Both must continue to give if they are no longer candidates. The Democratic Party is not in good financial shape. If Bloomberg loses, I would hope Sherrod Brown, senator of Ohio, would get in the race.

Bloomberg has credibility from his mayor terms and gun-control and climate-change work. But he was elected in a very liberal environment. Could he challenge Trump in red states?

You make a good point that Bloomberg might not go over well in red states where uneducated voters are abundant. Many Americans hate New Yorkers unfortunately, often for good reasons. But although Bloomberg is short in stature, many voters will realize that he would be the real alpha male in the race. He is tough and knowledgeable. He would take hard stands on many issues.

Handicap a Trump vs. Sanders contest.

Trump has already called Sanders a communist not a socialist, which he is. So we would have a rerun of Joe McCarthy. If Trump continues to call Sanders a communist, Democrats should call Trump and his ilk fascists. Down and dirty. I think Sanders would take the West Coast and most of the East Coast, including Florida.

But Trump would take states where education levels are low the South, and Northern states such as Montana, Wyoming, Idaho, North and South Dakota, Kansas, Nebraska and other traditionally red (redneck?) states. Colorado, New Mexico and even possibly Arizona could go for Sanders.

Ohio, Indiana and Iowa could go red and Wisconsin and Minnesota might go blue. Illinois could stay blue. Much depends on whether Americans realize that Trump is a pathological liar, sociopath, malignant psychotic narcissist. He seems totally out of control now.

Critics like Paul Heideman call Bloomberg a classic oligarch using his wealth to tilt the economic and political playing field in his favor. Can voters trust someone who uses vast wealth to gain support? How is billionaire Bloomberg better suited to the Oval Office than billionaire Steyer (or anyone else)?

Paul Heideman has a point. You are correct that some voters will see how many ads he spreads around and hold his wealth against him. But these people could be swayed by the wave of advertising.

What Bloomberg can do is massively sponsor ads that emphasize that Trump is a liar showing him saying one thing one day and the opposite the next day. Also, such ads could show that Trumps claims about the economy on his watch are false.

For example, Trump keeps repeating that the economy has done better under him than at other times. This is laughably false. GDP is growing a little over 2% now and there have been many times when it grew 3% and even 4%. Trump says unemployment is the lowest ever, and that is also false. These ads can also show Trump at his most vulgar. That might even go over well in redneck territory, however. Trumps racism through his dog whistles could be emphasized in certain markets but not in redneck areas.

Would Bloomberg address wealth inequality?

Bloomberg is strongly opposed to wealth inequality and says his own taxes should go up. However, he would only raise the corporate tax rate to 28% from 21%. Thats not enough, in my judgment. He believes income taxes for the rich should be boosted. He is also disgusted that taxes on stock and bond profits are lower than taxes on incomes.

He complains that economic growth is concentrated in a small number of regions. He would enhance worker rights and benefits although he has never been known as pro-union a possible negative. He wants a $15 minimum wage. He favors government-financed welfare projects. He would like to see rural communities better connected to urban growth centers. He wants to see research and development in regions needing development.

How is your health?

I saw my cardiologist just two weeks ago. I asked him if I was a candidate for a stent in my two arteries that are only moderately good. He said no. (Background: I have had two quadruple-bypass surgeries. The last one was in 1990. On average, the grafts last 30 years.) But cardiologists (I have had several) say this does not mean I have only two years to go.

The heart itself seems to be OK, but the concern is arteries or grafts from previous surgeries filling up. I will be 84 in May. I dont expect to make it to 90, but with lots of luck I may get half or a third of the way there.

San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg was last modified: February 15th, 2020 by Ken Stone

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read the rest here:
San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg - Times of San Diego